LifeScience Biologics
Waters Launches BD FACSDiscover A7 Cell Analyzer to Expand Access to Advanced Flow Cytometry
Waters Corporation announced the global commercial launch of the BD FACSDiscover™ A7 Cell Analyzer, which uniquely combines exceptional spectra...
September 17, 2026 | News
Altruist Biologics Supports LongBio Pharma’s LP-003 to NMPA BLA Acceptance in China
Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from c...
September 17, 2026 | News
AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer
AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial...
September 16, 2026 | News
Single Cell Discoveries Acquires TATAA Biocenter to Build Integrated Discovery-to-Validation CRO
Single Cell Discoveries (SCD), a specialist contract research organization (CRO) focused on discovery transcriptomics, has completed the acquisition of TAT...
September 16, 2026 | News
Icosagen, EPOK Advance Novel Antibody Therapy for Chronic Kidney Disease-Related Anaemia
Icosagen, a private European protein therapeutics CRDMO, and EPOK Therapeutics Inc., a pre-clinical-stage biopharmaceutical company, based in Toronto, Cana...
September 15, 2026 | News
IonOpticks Launches Aurora Series 5 to Boost Robustness in High-Throughput Proteomics
New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in r...
September 15, 2026 | News
Kelun-Biotech’s Trastuzumab Botidotin Cuts Progression Risk by 61% in Phase III Breast Cancer Study
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational...
September 15, 2026 | News
Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome
Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...
September 15, 2026 | News
TenNor’s TNP-2092 Shows 100% Treatment Success in Early, Acute PJI Phase IIa Trial
TenNor Therapeutics, a near-commercial-stage biotechnology company, announced positive topline results from a Phase IIa proof-of-concept (POC) trial of rif...
September 14, 2026 | News
Transcenta Licenses HiCB Bioprocessing Technology to WuXi Biologics in Strategic Collaboration
Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and proce...
September 11, 2026 | News
CordenPharma Invests €80M to Expand Sterile Injectable Manufacturing Capacity in Italy
CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional as...
September 11, 2026 | News
Solstice Oncology Launches with $225M Series A to Advance Harbour BioMed’s Porustobart
Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning...
September 11, 2026 | News
Kazia Doses First Patient in Phase II Study of Paxalisib Combination for Aggressive Paediatric Brain Cancer
Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies cur...
September 11, 2026 | News
Accro, Fosun Pharma Secure China Nod for Phase II/III Trial of AC-201 in Vitiligo
Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Indust...
September 10, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
